Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia

Cell

Volumn 168, Issue 1-2, 2017, Pages 59-72.e13

  Liang, Kaiwei ^a,b   Volk, Andrew G ^a   Haug, J S ^b   Marshall, Stacy A ^a   Woodfin, Ashley R ^a   Bartom, Elizabeth T ^a   Gilmore, Joshua M ^b   Florens, Laurence ^b   Washburn, Michael P ^b,c   Sullivan, Kelly D ^d   Espinosa, Joaquin M ^d   Cannova, Joseph ^e   Zhang, Jiwang ^e   Smith, Edwin R ^a   Crispino, John D ^a   Shilatifard, Ali ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

interleukin 1; IRAK1; IRAK4; mixed lineage leukemia; MLL; MLL chimera; SEC; super elongation complex; UBE2O; wild type MLL

Indexed keywords

INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; UBE2O PROTEIN; UNCLASSIFIED DRUG; HISTONE LYSINE METHYLTRANSFERASE; INTERLEUKIN 1; MLL PROTEIN, MOUSE; UBE2O PROTEIN, HUMAN; UBIQUITIN CONJUGATING ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; DOWN REGULATION; LEUKEMIA CELL; MOUSE; MURINE LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTEIN TARGETING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; HUMAN; LEUKEMIA, BIPHENOTYPIC, ACUTE; METABOLISM;

ANIMALS; DISEASE MODELS, ANIMAL; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LEUKEMIA, BIPHENOTYPIC, ACUTE; MICE; MICE, INBRED C57BL; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PROTEOLYSIS; UBIQUITIN-CONJUGATING ENZYMES;

EID: 85008462618     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.12.011     Document Type: Article

References (52)

1. Armstrong, S.A., Staunton, J.E., Silverman, L.B., Pieters, R., den Boer, M.L., Minden, M.D., Sallan, S.E., Lander, E.S., Golub, T.R., Korsmeyer, S.J., MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30 (2002), 41–47.
2. Borkin, D., He, S., Miao, H., Kempinska, K., Pollock, J., Chase, J., Purohit, T., Malik, B., Zhao, T., Wang, J., et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 27 (2015), 589–602.
3. Cao, F., Townsend, E.C., Karatas, H., Xu, J., Li, L., Lee, S., Liu, L., Chen, Y., Ouillette, P., Zhu, J., et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol. Cell 53 (2014), 247–261.
4. Dawson, M.A., Prinjha, R.K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.I., Robson, S.C., Chung, C.W., Hopf, C., Savitski, M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478 (2011), 529–533.
5. Singer, A. (2015). Epizyme announces second quarter 2015 financial results and provides corporate update. https://www.sec.gov/Archives/edgar/data/1571498/000119312515279839/d23584dex991.htm.
6. Fong, C.Y., Gilan, O., Lam, E.Y., Rubin, A.F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525 (2015), 538–542.
7. Gan, T., Jude, C.D., Zaffuto, K., Ernst, P., Developmentally induced Mll1 loss reveals defects in postnatal haematopoiesis. Leukemia 24 (2010), 1732–1741.
8. Guenther, M.G., Lawton, L.N., Rozovskaia, T., Frampton, G.M., Levine, S.S., Volkert, T.L., Croce, C.M., Nakamura, T., Canaani, E., Young, R.A., Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 22 (2008), 3403–3408.
9. Hanson, R.D., Hess, J.L., Yu, B.D., Ernst, P., van Lohuizen, M., Berns, A., van der Lugt, N.M., Shashikant, C.S., Ruddle, F.H., Seto, M., Korsmeyer, S.J., Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development. Proc. Natl. Acad. Sci. USA 96 (1999), 14372–14377.
10. Jones, W.D., Dafou, D., McEntagart, M., Woollard, W.J., Elmslie, F.V., Holder-Espinasse, M., Irving, M., Saggar, A.K., Smithson, S., Trembath, R.C., et al. De novo mutations in MLL cause Wiedemann-Steiner syndrome. Am. J. Hum. Genet. 91 (2012), 358–364.
11. Jude, C.D., Climer, L., Xu, D., Artinger, E., Fisher, J.K., Ernst, P., Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 1 (2007), 324–337.
12. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., Salzberg, S.L., TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol., 14, 2013, R36.
13. Kuo, H.P., Wang, Z., Lee, D.F., Iwasaki, M., Duque-Afonso, J., Wong, S.H., Lin, C.H., Figueroa, M.E., Su, J., Lemischka, I.R., Cleary, M.L., Epigenetic roles of MLL oncoproteins are dependent on NF-κB. Cancer Cell 24 (2013), 423–437.
14. Langmead, B., Trapnell, C., Pop, M., Salzberg, S.L., Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol., 10, 2009, R25.
15. Li, B.E., Ernst, P., Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Exp. Hematol. 42 (2014), 995–1012.
16. Li, Z., Younger, K., Gartenhaus, R., Joseph, A.M., Hu, F., Baer, M.R., Brown, P., Davila, E., Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J. Clin. Invest. 125 (2015), 1081–1097.
17. Liang, K., Gao, X., Gilmore, J.M., Florens, L., Washburn, M.P., Smith, E., Shilatifard, A., Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Mol. Cell. Biol. 35 (2015), 928–938.
18. Liang, K., Woodfin, A.R., Slaughter, B.D., Unruh, J.R., Box, A.C., Rickels, R.A., Gao, X., Haug, J.S., Jaspersen, S.L., Shilatifard, A., Mitotic transcriptional activation: clearance of actively engaged Pol II via transcriptional elongation control in mitosis. Mol. Cell 60 (2015), 435–445.
19. Lin, C., Smith, E.R., Takahashi, H., Lai, K.C., Martin-Brown, S., Florens, L., Washburn, M.P., Conaway, J.W., Conaway, R.C., Shilatifard, A., AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 37 (2010), 429–437.
20. Liu, Y., Cheng, H., Gao, S., Lu, X., He, F., Hu, L., Hou, D., Zou, Z., Li, Y., Zhang, H., et al. Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells. Leukemia 28 (2014), 1071–1080.
21. Lu, T., Jackson, M.W., Singhi, A.D., Kandel, E.S., Yang, M., Zhang, Y., Gudkov, A.V., Stark, G.R., Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc. Natl. Acad. Sci. USA 106 (2009), 16339–16344.
22. Mashtalir, N., Daou, S., Barbour, H., Sen, N.N., Gagnon, J., Hammond-Martel, I., Dar, H.H., Therrien, M., Affar, B., Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Mol. Cell 54 (2014), 392–406.
23. McMahon, K.A., Hiew, S.Y., Hadjur, S., Veiga-Fernandes, H., Menzel, U., Price, A.J., Kioussis, D., Williams, O., Brady, H.J., Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 1 (2007), 338–345.
24. Meyer, C., Hofmann, J., Burmeister, T., Gröger, D., Park, T.S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., et al. The MLL recombinome of acute leukemias in 2013. Leukemia 27 (2013), 2165–2176.
25. Mi, H., Muruganujan, A., Casagrande, J.T., Thomas, P.D., Large-scale gene function analysis with the PANTHER classification system. Nat. Protoc. 8 (2013), 1551–1566.
26. Miller, T., Krogan, N.J., Dover, J., Erdjument-Bromage, H., Tempst, P., Johnston, M., Greenblatt, J.F., Shilatifard, A., COMPASS: a complex of proteins associated with a trithorax-related SET domain protein. Proc. Natl. Acad. Sci. USA 98 (2001), 12902–12907.
27. Milne, T.A., Kim, J., Wang, G.G., Stadler, S.C., Basrur, V., Whitcomb, S.J., Wang, Z., Ruthenburg, A.J., Elenitoba-Johnson, K.S., Roeder, R.G., Allis, C.D., Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol. Cell 38 (2010), 853–863.
28. Mishra, B.P., Zaffuto, K.M., Artinger, E.L., Org, T., Mikkola, H.K., Cheng, C., Djabali, M., Ernst, P., The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. Cell Rep. 7 (2014), 1239–1247.
29. Mohan, M., Herz, H.M., Takahashi, Y.H., Lin, C., Lai, K.C., Zhang, Y., Washburn, M.P., Florens, L., Shilatifard, A., Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 24 (2010), 574–589.
30. Mohan, M., Lin, C., Guest, E., Shilatifard, A., Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat. Rev. Cancer 10 (2010), 721–728.
31. Nguyen, A.T., Taranova, O., He, J., Zhang, Y., DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117 (2011), 6912–6922.
32. Okuda, H., Kawaguchi, M., Kanai, A., Matsui, H., Kawamura, T., Inaba, T., Kitabayashi, I., Yokoyama, A., MLL fusion proteins link transcriptional coactivators to previously active CpG-rich promoters. Nucleic Acids Res. 42 (2014), 4241–4256.
33. Pigneux, A., Labopin, M., Maertens, J., Cordonnier, C., Volin, L., Socié, G., Blaise, D., Craddock, C., Milpied, N., Bacher, U., et al., Acute Leukemia Working Party EBMT. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). Leukemia 29 (2015), 2375–2381.
34. Powers, J.P., Li, S., Jaen, J.C., Liu, J., Walker, N.P., Wang, Z., Wesche, H., Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg. Med. Chem. Lett. 16 (2006), 2842–2845.
35. Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J.S., Muhar, M., Deswal, S., Cerny-Reiterer, S., Peter, B., Jude, J., et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525 (2015), 543–547.
36. Rhyasen, G.W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24 (2013), 90–104.
37. Robinson, M.D., McCarthy, D.J., Smyth, G.K., edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26 (2010), 139–140.
38. Shen, L., Shao, N., Liu, X., Nestler, E., ngs.plot: Quick mining and visualization of next-generation sequencing data by integrating genomic databases. BMC Genomics, 15, 2014, 284.
39. Shilatifard, A., The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu. Rev. Biochem. 81 (2012), 65–95.
40. Smith, E., Lin, C., Shilatifard, A., The super elongation complex (SEC) and MLL in development and disease. Genes Dev. 25 (2011), 661–672.
41. Thiel, A.T., Blessington, P., Zou, T., Feather, D., Wu, X., Yan, J., Zhang, H., Liu, Z., Ernst, P., Koretzky, G.A., Hua, X., MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 17 (2010), 148–159.
42. Tomizawa, D., Koh, K., Sato, T., Kinukawa, N., Morimoto, A., Isoyama, K., Kosaka, Y., Oda, T., Oda, M., Hayashi, Y., et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 21 (2007), 2258–2263.
43. Tripathi, S., Pohl, M.O., Zhou, Y., Rodriguez-Frandsen, A., Wang, G., Stein, D.A., Moulton, H.M., DeJesus, P., Che, J., Mulder, L.C., et al. Meta- and orthogonal integration of influenza “OMICs” data defines a role for UBR4 in virus budding. Cell Host Microbe 18 (2015), 723–735.
44. Tumey, L.N., Boschelli, D.H., Bhagirath, N., Shim, J., Murphy, E.A., Goodwin, D., Bennett, E.M., Wang, M., Lin, L.L., Press, B., et al. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4. Bioorg. Med. Chem. Lett. 24 (2014), 2066–2072.
45. Volk, A., Li, J., Xin, J., You, D., Zhang, J., Liu, X., Xiao, Y., Breslin, P., Li, Z., Wei, W., et al. Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML. J. Exp. Med. 211 (2014), 1093–1108.
46. Wang, P., Lin, C., Smith, E.R., Guo, H., Sanderson, B.W., Wu, M., Gogol, M., Alexander, T., Seidel, C., Wiedemann, L.M., et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol. Cell. Biol. 29 (2009), 6074–6085.
47. Wang, Q.F., Wu, G., Mi, S., He, F., Wu, J., Dong, J., Luo, R.T., Mattison, R., Kaberlein, J.J., Prabhakar, S., et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 117 (2011), 6895–6905.
48. Whitman, S.P., Liu, S., Vukosavljevic, T., Rush, L.J., Yu, L., Liu, C., Klisovic, M.I., Maharry, K., Guimond, M., Strout, M.P., et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 106 (2005), 345–352.
49. Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I., Cleary, M.L., A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17 (2010), 198–212.
50. Yokoyama, A., Ficara, F., Murphy, M.J., Meisel, C., Naresh, A., Kitabayashi, I., Cleary, M.L., Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways. J. Cell Sci. 124 (2011), 2208–2219.
51. Yu, B.D., Hess, J.L., Horning, S.E., Brown, G.A., Korsmeyer, S.J., Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378 (1995), 505–508.
52. Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., Liu, X.S., Model-based analysis of ChIP-Seq (MACS). Genome Biol., 9, 2008, R137.